Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22095Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rizos, E. C. | en |
| dc.contributor.author | Spyrou, A. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Papavasiliou, E. C. | en |
| dc.contributor.author | Saougos, V. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:21:20Z | - |
| dc.date.available | 2015-11-24T19:21:20Z | - |
| dc.identifier.issn | 1874-1924 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22095 | - |
| dc.rights | Default Licence | - |
| dc.title | Effects of eprosartan on serum metabolic parameters in patients with essential hypertension | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.2174/1874192400701010022 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18949087 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | The effect of the anti-hypertensive drug eprosartan on metabolic parameters is currently not extensively documented. We evaluated the effect of eprosartan on parameters involved in atherogenesis, oxidative stress and clotting activity. This open-label unblinded intervention study included 40 adult patients with essential hypertension taking eprosartan. Eprosartan significantly reduced by 8% (p<0.001) the systolic and by 13% (p<.001) the diastolic blood pressure, and in-creased by 24% the time needed to produce oxidative by-products (p=0.001), a marker of oxidative stress. In contrast, ep-rosartan did not alter 8-isoprostane (8-epiPGF2a) levels, another marker of oxidative stress. Additionally, eprosartan re-duced by 14% aspartate aminotransferase and by 21% then alanine aminotransferase activity, while it had a neutral effect on the lipid profile and apolipoprotein levels and did not influence glucose homeostasis, creatinine and uric acid levels. Eprosartan did not affect the clotting/fibrinolytic status (estimated by plasminogen activator inhibitor 1, tissue plasmino-gen activator and a2 antiplasmin levels), or the enzymatic activity of the lipoprotein associated phospholipase A2 (Lp-PLA2) and paraoxonase 1 (PON1). In conclusion, eprosartan should be mainly considered as an anti-hypertensive agent with neutral effects on most of the metabolic parameters in hypertensive patients. | en |
| heal.journalName | Open Cardiovasc Med J | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Elisaf-2007-effects of eprosartan.pdf | 121.26 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
